Epidermal growth factor and betacellulin mediate signal transduction through co‐expressed ErbB2 and ErbB3 receptors

Interleukin‐3 (IL‐3)‐dependent murine 32D cells do not detectably express epidermal growth factor receptors (EGFRs) and do not proliferate in response to EGF, heregulin (HRG) or other known EGF‐like ligands. Here, we report that EGF specifically binds to and can be crosslinked to 32D transfectants co‐expressing ErbB2 and ErbB3 (32D.E2/E3), but not to transfectants expressing either ErbB2 or ErbB3 individually. [125I]EGF‐crosslinked species detected in 32D.E2/E3 cells were displaced by HRG and betacellulin (BTC) but not by other EGF‐like ligands that were analyzed. EGF, BTC and HRG also induced receptor tyrosine phosphorylation, activation of downstream signaling molecules and proliferation of 32D.E2/E3 cells. 32D transfectants were also generated which expressed an ErbB3–EGFR chimera alone (32D.E3‐E1) or in combination with ErbB2 (32D.E2/E3‐E1). While HRG stimulation of 32D.E3‐E1 cells resulted in DNA synthesis and receptor phosphorylation, EGF and BTC were inactive. However, EGF and BTC were as effective as HRG in mediating signaling when ErbB2 was co‐expressed with the chimera in the 32D.E2/E3‐E1 transfectant. These results provide evidence that ErbB2/ErbB3 binding sites for EGF and BTC are formed by a previously undescribed mechanism that requires co‐expression of two distinct receptors. Additional data utilizing MDA MB134 human breast carcinoma cells, which naturally express ErbB2 and ErbB3 in the absence of EGFRs, supported the results obtained employing 32D cells and suggest that EGF and BTC may contribute to the progression of carcinomas that co‐express ErbB2 and ErbB3.

[1]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[2]  M. Klagsbrun,et al.  Activation of HER4 by heparin‐binding EGF‐like growth factor stimulates chemotaxis but not proliferation , 1997, The EMBO journal.

[3]  D. Engelman,et al.  Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.

[4]  M. Klagsbrun,et al.  The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4* , 1996, The Journal of Biological Chemistry.

[5]  Y. Yarden,et al.  Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations* , 1996, The Journal of Biological Chemistry.

[6]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[7]  T. Arakawa,et al.  Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. , 1996, Biochemistry.

[8]  T. van Raaij,et al.  Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. , 1996, Oncogene.

[9]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[10]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[11]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[12]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[13]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[14]  L. Cantley,et al.  Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3(*) , 1995, The Journal of Biological Chemistry.

[15]  T. Isobe,et al.  Epiregulin , 1995, The Journal of Biological Chemistry.

[16]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[17]  D. Taverna,et al.  NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. , 1995, Oncogene.

[18]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[19]  E. Peles,et al.  ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. , 1994, The Journal of biological chemistry.

[20]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  W. Gullick,et al.  NDF/heregulin stimulates the phosphorylation of Her3/erbB3 , 1994, FEBS letters.

[22]  L. Cantley,et al.  A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.

[23]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[24]  W. Gullick,et al.  Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.

[25]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[26]  L. Cantley,et al.  The erbB3 gene product is a receptor for heregulin. , 1994, The Journal of biological chemistry.

[27]  M. Kraus,et al.  Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members , 1994, Molecular and cellular biology.

[28]  G. Plowman,et al.  Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 , 1993, Nature.

[29]  Y. Yarden,et al.  Neu and its ligands: From an oncogene to neural factors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[30]  L. Minichiello,et al.  Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF‐dependent mitogenic signals. , 1993, The EMBO journal.

[31]  M. White,et al.  IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. , 1993, Science.

[32]  M. Waterfield,et al.  Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system , 1993, Nature.

[33]  D. Hanahan,et al.  Betacellulin: a mitogen from pancreatic beta cell tumors. , 1993, Science.

[34]  William Arbuthnot Sir Lane,et al.  ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family , 1993, Cell.

[35]  Y. Yarden,et al.  Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships. , 1993, The EMBO journal.

[36]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[38]  R. Koski,et al.  Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit , 1992, Cell.

[39]  Yosef Yarden,et al.  Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.

[40]  K. Clauser,et al.  Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. , 1991, Science.

[41]  M. Klagsbrun,et al.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF , 1991, Science.

[42]  S. Aaronson,et al.  The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. , 1990, The New biologist.

[43]  Masui,et al.  Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[44]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[45]  S. Aaronson,et al.  EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. , 1990, Science.

[46]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Merlo,et al.  mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients. , 1989, Journal of the National Cancer Institute.

[48]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[49]  G. Plowman,et al.  Structure and function of human amphiregulin: a member of the epidermal growth factor family. , 1989, Science.

[50]  R. Derynck,et al.  Transforming growth factor α , 1988, Cell.

[51]  T. Powles,et al.  Growth factor expression in normal, benign, and malignant breast tissue , 1988, British medical journal.

[52]  S. Bates,et al.  Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. , 1988, Molecular endocrinology.

[53]  J. Schlessinger,et al.  Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. , 1988, Science.

[54]  D. Goeddel,et al.  Synthesis of Messenger RNAs for Transforming Growth Factors α and β and the Epidermal Growth Factor Receptor by Human Tumors , 1987 .

[55]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[56]  H. Moses,et al.  Growth factors and cancer. , 1986, Cancer research.

[57]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[58]  L. Hood,et al.  Rat transforming growth factor type 1: structure and relation to epidermal growth factor. , 1984, Science.

[59]  B. Weissman,et al.  BALB and kirsten murine sarcoma viruses alter growth and differentiation of EGF-dependent BALB/c mouse epidermal keratinocyte lines , 1983, Cell.

[60]  S. Cohen,et al.  The primary structure of epidermal growth factor. , 1972, The Journal of biological chemistry.

[61]  W. N. Bailey.  An expression for , 1953 .

[62]  A. Burgess,et al.  Structure-Function relationships for the EGF/TGF-α family of mitogens , 1994 .

[63]  W. Gullick,et al.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. , 1991, British medical bulletin.

[64]  T. Fleming,et al.  Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. , 1989, Oncogene.